Brought to you by 
Sunovion buys Elevation Pharmaceuticals for up to $430mm
23 Oct 2012
Executive Summary
Dainippon Sumitomo Pharma Co. Ltd.’s Sunovion Pharmaceuticals Inc. (mainly CNS and respiratory treatments) has agreed to acquire closely held respiratory therapeutics developer Elevation Pharmaceuticals Inc. for $100mm, plus up to $330mm in earn-outs: $90mm based on the successful development of EP101, another $210mm for reaching commercialization goals pertaining to the drug candidate, and $30mm for the development of additional programs. EP101 is in Phase II for moderate-to-severe chronic obstructive pulmonary disease and should begin Phase III during 2H 2013. The company claims it is the only long-acting, nebulized bronchodilator in development.
Deal Industry
- Biotechnology
- Pharmaceuticals
-
Pharmaceuticals
-
Drug Delivery
- Pulmonary
-
Drug Delivery
Deal Status
- Final
Deal Type
-
Acquisition
- Acquisition of Private Biotech
- Full Acquisition
- Includes Earnout
- Payment Includes Cash
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Sunovion buys Elevation Pharmaceuticals for up to $430mm
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice